BioSpace19m
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...
BioSpace1h
The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty
The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...
BioSpace8h
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
BioSpace8h
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
BioSpace2d
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
BioSpace2d
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
BioSpace2d
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...
BioSpace2d
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
BioSpace2d
6 Rare Diseases That Have New FDA-Approved Treatments
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
BioSpace2d
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
BioSpace2d
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...
BioSpace3d
Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates
Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes ...